SHARGEL & YU'S

APPLIED BIOPHARMACEUTICS AND PHARMACOKINETICS

SEVENTH EDITION

LEON SHARGEL ANDREW B.C. YU





Applied Biopharmaceutics & Pharmacokinetics

Seventh Edition

EDITORS

Leon Shargel, PHD, RPh

Applied Biopharmaceutics, LLC Raleigh, North Carolina Affiliate Professor, School of Pharmacy Virginia Commonwealth University, Richmond, Virginia Adjunct Associate Professor, School of Pharmacy University of Maryland, Baltimore, Maryland

Andrew B.C. Yu, PHD, RPh

Registered Pharmacist Gaithersburg, Maryland Formerly Associate Professor of Pharmaceutics Albany College of Pharmacy Albany, New York Formerly CDER, FDA Silver Spring, Maryland



New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto

Applied Biopharmaceutics & Pharmacokinetics, Seventh Edition

Copyright © 2016 by McGraw-Hill Education. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

Previous editions copyright © 2012 by The McGraw-Hill Companies, Inc.; © 2005, 1999, 1993 by Appleton & Lange; © 1985, 1980 by Appleton-Century-Crofts.

1 2 3 4 5 6 7 8 9 0 DOC/DOC 20 19 18 17 16 15

ISBN 978-0-07-183093-5 MHID 0-07-183093-6

This book was set in Times LT Std by Cenveo® Publisher Services.

The editors were Michael Weitz and Regina Y. Brown.

The production supervisor was Rick Ruzycka.

The production manager was Tanya Punj, Cenveo Publisher Services.

The design was by Elise Lansdon; the cover design was by Barsoom Design, with cover art © Gregor Schuster/Corbis. RR Donnelley was printer and binder.

Library of Congress Cataloging-in-Publication Data

Shargel, Leon, 1941-, author.

Applied biopharmaceutics & pharmacokinetics / Leon Shargel, Andrew B.C. Yu.-Seventh edition.

p. ; cm.

Applied biopharmaceutics and pharmacokinetics

Includes bibliographical references and index.

ISBN 978-0-07-183093-5 (hardcover)—ISBN 0-07-183093-6 (hardcover)

I. Yu, Andrew B. C., 1945-, author. II. Title. III. Title: Applied biopharmaceutics and pharmacokinetics.

[DNLM: 1. Biopharmaceutics. 2. Pharmacokinetics. 3. Drug Administration Routes. 4. Models, Chemical. QV 38] RM301.4

615.7-dc23

2015014810

McGraw-Hill books are available at special quantity discounts to use as premiums and sales promotions, or for use in corporate training programs. To contact a representative please e-mail us at bulksales@mcgraw-hill.com.

Contents

Contributors xi Preface xv Preface to First Edition xvii

1. Introduction to Biopharmaceutics and Pharmacokinetics 1

Drug Product Performance 1 **Biopharmaceutics** 1 Pharmacokinetics 4 Pharmacodynamics 4 Clinical Pharmacokinetics 5 Practical Focus 8 Pharmacodynamics 10 Drug Exposure and Drug Response 10 Toxicokinetics and Clinical Toxicology 10 Measurement of Drug Concentrations 11 Basic Pharmacokinetics and Pharmacokinetic Models 15 Chapter Summary 21 Learning Questions 22 Answers 23 References 25 Bibliography 25

2. Mathematical Fundamentals in Pharmacokinetics 27

Calculus 27 Graphs 29 Practice Problem 31 Mathematical Expressions and Units 33 Units for Expressing Blood Concentrations 34 Measurement and Use of Significant Figures 34 Practice Problem 35 Practice Problem 36 Rates and Orders of Processes 40 Chapter Summary 42 Learning Questions 43 Answers 46 References 50

3. Biostatistics 51 Variables 51 Types of Data (Nonparametric Versus Parametric) 51 Distributions 52 Measures of Central Tendency 53 Measures of Variability 54 Hypothesis Testing 56 Statistically Versus Clinically Significant Differences 58 Statistical Inference Techniques in Hypothesis Testing for Parametric Data 59 Goodness of Fit 63 Statistical Inference Techniques for Hypothesis Testing With Nonparametric Data 63 Controlled Versus Noncontrolled Studies 66 Blinding 66 Confounding 66 Validity 67 Bioequivalence Studies 68 Evaluation of Risk for Clinical Studies 68 Chapter Summary 70 Learning Questions 70 Answers 72 References 73

4. One-Compartment Open Model: Intravenous Bolus Administration 75

Elimination Rate Constant 76 Apparent Volume of Distribution 77 Clearance 80 Clinical Application 85 Calculation of *k* From Urinary Excretion Data 86 Practice Problem 87 Practice Problem 88 Clinical Application 89 Chapter Summary 90 Learning Questions 90 Answers 92 Reference 96 Bibliography 96

Multicompartment Models: Intravenous Bolus Administration 97 Two-Compartment Open Model 100 Clinical Application 105

V

vi CONTENTS

Practice Problem 107 Practical Focus 107 Practice Problem 110 Practical Focus 113 Three-Compartment Open Model 114 Clinical Application 115 Clinical Application 116 Determination of Compartment Models 116 Practical Focus 117 Clinical Application 118 Practical Problem 120 Clinical Application 121 Practical Application 121 Clinical Application 122 Chapter Summary 123 Learning Questions 124 Answers 126 References 128 Bibliography 129

6. Intravenous Infusion 131

One-Compartment Model Drugs 131 Infusion Method for Calculating Patient Elimination Half-Life 135 Loading Dose Plus IV Infusion-One-Compartment Model 136 Practice Problems 138 Estimation of Drug Clearance and V_D From Infusion Data 140 Intravenous Infusion of Two-Compartment Model Drugs 141 Practical Focus 142 Chapter Summary 144 Learning Questions 144 Answers 146 Reference 148 Bibliography 148

7. Drug Elimination, Clearance, and **Renal Clearance** 149 Drug Elimination 149 Drug Clearance 150 Clearance Models 152 The Kidney 157 Clinical Application 162 Practice Problems 163 Renal Clearance 163 Determination of Renal Clearance 168 Practice Problem 169 Practice Problem 169 Relationship of Clearance to Elimination Half-Life and Volume of Distribution 170 Chapter Summary 171 Learning Questions 171 Answers 172

References 175 Bibliography 175

8. Pharmacokinetics of Oral

Absorption 177 Introduction 177 Basic Principles of Physiologically Based Absorption Kinetics (Bottom-Up Approach) 178 Absoroption Kinetics (The Top-Down Approach) 182 Pharmacokinetics of Drug Absorption 182 Significance of Absorption Rate Constants 184 Zero-Order Absorption Model 184 Clinical Application—Transdermal Drug Delivery 185 First-Order Absorption Model 185 Practice Problem 191 Chapter Summary 199 Answers 200 Application Questions 202 References 203 Bibliography 204

9. Multiple-Dosage Regimens 205

Drug Accumulation 205 Clinical Example 209 Repetitive Intravenous Injections 210 Intermittent Intravenous Infusion 214 Clinical Example 216 Estimation of \hat{k} and $V_{\rm D}$ of Aminoglycosides in Clinical Situations 217 Multiple-Oral-Dose Regimen 218 Loading Dose 219 Dosage Regimen Schedules 220 Clinical Example 222 Practice Problems 222 Chapter Summary 224 Learning Questions 225 Answers 226 References 228 Bibliography 228

10. Nonlinear Pharmacokinetics 229

Saturable Enzymatic Elimination Processes 231 Practice Problem 232 Practice Problem 233 Drug Elimination by Capacity-Limited Pharmacokinetics: One-Compartment Model, IV Bolus Injection 233 Practice Problems 235 Clinical Focus 242 Clinical Focus 243 Drugs Distributed as One-Compartment Model and Eliminated by Nonlinear Pharmacokinetics 243 Clinical Focus 244 Chronopharmacokinetics and Time-Dependent Pharmacokinetics 245 Clinical Focus 247 Bioavailability of Drugs That Follow Nonlinear Pharmacokinetics 247 Nonlinear Pharmacokinetics Due to Drug-Protein Binding 248 Potential Reasons for Unsuspected Nonlinearity 251 Dose-Dependent Pharmacokinetics 252 Clinical Example 253 Chapter Summary 254 Learning Questions 254 Answers 255 References 257 Bibliography 258

11. Physiologic Drug Distribution and Protein Binding 259

Physiologic Factors of Distribution 259 Clinical Focus 267 Apparent Volume Distribution 267 Practice Problem 270 Protein Binding of Drugs 273 Clinical Examples 275 Effect of Protein Binding on the Apparent Volume of Distribution 276 Practice Problem 279 Clinical Example 280 Relationship of Plasma Drug-Protein Binding to Distribution and Elimination 281 Clinical Examples 282 Clinical Example 284 Determinants of Protein Binding 285 Clinical Example 285 Kinetics of Protein Binding 286 Practical Focus 287 Determination of Binding Constants and Binding Sites by Graphic Methods 287 Clinical Significance of Drug-Protein Binding 290 Clinical Example 299 Clinical Example 300 Modeling Drug Distribution 301 Chapter Summary 302 Learning Questions 303 Answers 304 References 306 Bibliography 307

12. Drug Elimination and Hepatic Clearance 309

Route of Drug Administration and Extrahepatic Drug Metabolism 309 Practical Focus 311 Hepatic Clearance 311 Extrahepatic Metabolism 312 Enzyme Kinetics-Michaelis-Menten Equation 313 Clinical Example 317 Practice Problem 319 Anatomy and Physiology of the Liver 321 Hepatic Enzymes Involved in the Biotransformation of Drugs 323 Drug Biotransformation Reactions 325 Pathways of Drug Biotransformation 326 Drug Interaction Example 331 Clinical Example 338 First-Pass Effects 338 Hepatic Clearance of a Protein-Bound Drug: Restrictive and Nonrestrictive Clearance From Binding 344 Biliary Excretion of Drugs 346 Clinical Example 348 Role of Transporters on Hepatic Clearance and Bioavailability 348 Chapter Summary 350 Learning Questions 350 Answers 352 References 354 Bibliography 355

13. Pharmacogenetics and Drug Metabolism 357 Genetic Polymorphisms 358

Cytochrome P-450 Isozymes 361 Phase II Enzymes 366 Transporters 367 Chapter Summary 368 Glossary 369 Abbreviations 369 References 370

14. Physiologic Factors Related to Drug Absorption 373

Drug Absorption and Design of a Drug Product 373
Route of Drug Administration 374
Nature of Cell Membranes 377
Passage of Drugs Across Cell Membranes 378
Drug Interactions in the Gastrointestinal Tract 389
Oral Drug Absorption 390
Oral Drug Absorption During Drug Product Development 401
Methods for Studying Factors That Affect Drug Absorption 402
Effect of Disease States on Drug Absorption 405
Miscellaneous Routes of Drug Administration 407 Chapter Summary 408 Learning Questions 409 Answers to Questions 410 References 411 Bibliography 414

15. Biopharmaceutic Considerations in Drug Product Design and *In Vitro* Drug Product Performance 415

Biopharmaceutic Factors and Rationale for Drug Product Design 416 Rate-Limiting Steps in Drug Absorption 418 Physicochemical Properties of the Drug 420 Formulation Factors Affecting Drug Product Performance 423 Drug Product Performance, In Vitro: Dissolution and Drug Release Testing 425 Compendial Methods of Dissolution 429 Alternative Methods of Dissolution Testing 431 Dissolution Profile Comparisons 434 Meeting Dissolution Requirements 436 Problems of Variable Control in Dissolution Testing 437 Performance of Drug Products: In Vitro-In Vivo Correlation 437 Approaches to Establish Clinically Relevant Drug Product Specifications 441 Drug Product Stability 445 Considerations in the Design of a Drug Product 446 Drug Product Considerations 450 Clinical Example 456 Chapter Summary 461 Learning Questions 462 Answers 462 References 463 Bibliography 466

16. Drug Product Performance, In Vivo: **Bioavailability and Bioequivalence** 469 Drug Product Performance 469 Purpose of Bioavailability and Bioequivalence Studies 471 Relative and Absolute Availability 472 Practice Problem 474 Methods for Assessing Bioavailability and Bioequivalence 475 In Vivo Measurement of Active Moiety or Moieties in Biological Fluids 475 Bioequivalence Studies Based on Pharmacodynamic Endpoints-In Vivo Pharmacodynamic (PD) Comparison 478 Bioequivalence Studies Based on Clinical Endpoints-Clinical Endpoint Study 479 In Vitro Studies 481

Other Approaches Deemed Acceptable (by the FDA) 482 Bioequivalence Studies Based on Multiple Endpoints 482 Bioequivalence Studies 482 Design and Evaluation of Bioequivalence Studies 484 Study Designs 490 Crossover Study Designs 491 Clinical Example 496 Clinical Example 496 Pharmacokinetic Evaluation of the Data 497 The Partial AUC in Bioequivalence Analysis 498 Examples of Partial AUC Analyses 499 Bioequivalence Examples 500 Study Submission and Drug Review Process 502 Waivers of In Vivo Bioequivalence Studies (Biowaivers) 503 The Biopharmaceutics Classification System (BCS) 507 Generic Biologics (Biosimilar Drug Products) 510 Clinical Significance of Bioequivalence Studies 511 Special Concerns in Bioavailability and Bioequivalence Studies 512 Generic Substitution 514 Glossary 517 Chapter Summary 520 Learning Questions 520 Answers 525 References 526

17. Biopharmaceutical Aspects of the **Active Pharmaceutical Ingredient and** Pharmaceutical Equivalence 529 Introduction 529 Pharmaceutical Alternatives 533 Practice Problem 534 Bioequivalence of Drugs With Multiple Indications 536 Formulation and Manufacturing Process Changes 536 Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules 536 Changes to an Approved NDA or ANDA 537 The Future of Pharmaceutical Equivalence and Therapeutic Equivalence 538 Biosimilar Drug Products 539 Historical Perspective 540 Chapter Summary 541 Learning Ouestions 541

Answers 542 References 542

7

18. Impact of Biopharmaceutics on Drug Product Quality and Clinical Efficacy 545

Risks From Medicines 545 Risk Assessment 546 Drug Product Quality and Drug Product Performance 547 Pharmaceutical Development 547 Example of Quality Risk 550 Excipient Effect on Drug Product Performance 553 Practical Focus 554 Quality Control and Quality Assurance 554 Practical Focus 555 Risk Management 557 Scale-Up and Postapproval Changes (SUPAC) 558 Practical Focus 561 Product Quality Problems 561 Postmarketing Surveillance 562 Glossary 562 Chapter Summary 563 Learning Questions 564 Answers 564 References 565 Bibliography 565

19. Modified-Release Drug Products and Drug Devices 567 Modified-Release (MR) Drug Products and Conventional (Immediate-Release, IR) Drug Products 567 Biopharmaceutic Factors 572 Dosage Form Selection 575 Advantages and Disadvantages of Extended-Release Products 575 Kinetics of Extended-Release Dosage Forms 577 Pharmacokinetic Simulation of Extended-Release Products 578 Clinical Examples 580 Types of Extended-Release Products 581 Considerations in the Evaluation of Modified-Release Products 601 Evaluation of Modified-Release Products 604 Evaluation of In Vivo Bioavailability Data 606 Chapter Summary 608 Learning Questions 609 References 609 Bibliography 613

20. Targeted Drug Delivery Systems and Biotechnological Products 615 Biotechnology 615

Drug Carriers and Targeting 624 Targeted Drug Delivery 627 Pharmacokinetics of Biopharmaceuticals 630 Bioequivalence of Biotechnology-Derived Drug Products 631 Learning Questions 632 Answers 632 References 633 Bibliography 633

21. Relationship Between Pharmacokinetics and Pharmacodynamics 635

Pharmacokinetics and Pharmacodynamics 635
Relationship of Dose to Pharmacologic Effect 640
Relationship Between Dose and Duration of Activity (t_{eff}), Single IV Bolus Injection 643
Practice Problem 643
Effect of Both Dose and Elimination Half-Life on the Duration of Activity 643
Effect of Elimination Half-Life on Duration of Activity 644
Substance Abuse Potential 644
Drug Tolerance and Physical Dependency 645
Hypersensitivity and Adverse Response 646
Chapter Summary 673
Learning Questions 674
Answers 677
References 678

References 6/8

22. Application of Pharmacokinetics to Clinical Situations 681

Medication Therapy Management 681 Individualization of Drug Dosage Regimens 682 Therapeutic Drug Monitoring 683 Clinical Example 690 Clinical Example 692 Design of Dosage Regimens 692 Conversion From Intravenous Infusion to Oral Dosing 694 Determination of Dose 696 Practice Problems 696 Effect of Changing Dose ond Dosing Interval on $C_{\max}^{\infty}, C_{\min}^{\infty}, \text{ and } C_{\max}^{\infty}$ 697 Determination of Frequency of Drug Administration 698 Determination of Both Dose and Dosage Interval 698 Practice Problem 699 Determination of Route of Administration 699 Dosing Infants and Children 700 Practice Problem 702 Dosing the Elderly 702 Practice Problems 703 Clinical Example 704 Dosing the Obese Patients 705 Pharmacokinetics of Drug Interactions 706 Inhibition of Drug Metabolism 710

X CONTENTS

Inhibition of Monoamine Oxidase (MAO) 712 Induction of Drug Metabolism 712 Inhibition of Drug Absorption 712 Inhibition of Biliary Excretion 713 Altered Renal Reabsorption Due to Changing Urinary pH 713 Practical Focus 713 Effect of Food on Drug Disposition 713 Adverse Viral Drug Interactions 714 Population Pharmacokinetics 714 Clinical Example 722 **Regional Pharmacokinetics** 724 Chapter Summary 725 Learning Questions 725 Answers 728 References 731 Bibliography 732

23. Application of Pharmacokinetics to Specific Populations: Geriatric, Obese, and Pediatric Patients 735

Specific and Special Populations 735 Module I: Application of Pharmacokinetics to the Geriatric Patients 736 Summary 749 Learning Questions 749 Answers 750 References 751 Further Reading 754 Module II: Application of Pharmacokinetics to the Obese Patients 754 Summary 760 Learning Questions 760 Answers 761 References 761 Module III: Application of Pharmacokinetics to the Pediatric Patients 763 Summary 769 Learning Questions 770 Answers 771 References 773

24. Dose Adjustment in Renal and Hepatic

Disease 775

Renal Impairment 775 Pharmacokinetic Considerations 775 General Approaches for Dose Adjustment in Renal Disease 777 Measurement of Glomerular Filtration Rate 779 Serum Creatinine Concentration and Creatinine Clearance 780 Practice Problems 782 Dose Adjustment for Uremic Patients 785 Practice Problem 787 Practice Problem 792 Practice Problems 793 Practice Problem 795 Extracorporeal Removal of Drugs 796 Practice Problem 799 Clinical Examples 800 Effect of Hepatic Disease on Pharmacokinetics 803 Practice Problem 805 Chapter Summary 809 Learning Questions 810 Answers 811 References 813 Bibliography 815

25. Empirical Models, Mechanistic Models, Statistical Moments, and Noncompartmental Analysis 817 Empirical Models 818 Mechanistic Models 822 Noncompartmental Analysis 835 Comparison of Different Approaches 842 Selection of Pharmacokinetic Models 844 Chapter Summary 845 Learning Questions 845 Answers 846 References 847 Bibliography 848

Appendix A Applications of Software Packages in Pharmacokinetics 851

Appendix B Glossary 875

Index 879



Multiple-Dosage Regimens

Rodney C. Siwale and Shabnam N. Sani

Chapter Objectives

- Define the index for measuring drug accumulation.
- Define drug accumulation and drug accumulation t_{1/2}.
- Explain the principle of superposition and its assumptions in multiple-dose regimens.
- Calculate the steady-state C_{max} and C_{min} after multiple IV bolus dosing of drugs.
- Calculate k and V_D of aminoglycosides in multipledose regimens.
- Adjust the steady-state C_{max} and C_{min} in the event the last dose is given too early, too late, or totally missed following multiple IV dosing.

Earlier chapters of this book discussed single-dose drug and constant-rate drug administration. By far though, most drugs are given in several doses, for example, multiple doses to treat chronic disease such as arthritis, hypertension, etc. After single-dose drug administration, the plasma drug level rises above and then falls below the minimum effective concentration (MEC), resulting in a decline in therapeutic effect. To treat chronic disease, multipledosage or IV infusion regimens are used to maintain the plasma drug levels within the narrow limits of the therapeutic window (eg, plasma drug concentrations above the MEC but below the minimum toxic concentration or MTC) to achieve optimal clinical effectiveness. These drugs may include antibacterials, cardiotonics, anticonvulsants, hypoglycemics, antihypertensives, hormones, and others. Ideally, a dosage regimen is established for each drug to provide the correct plasma level without excessive fluctuation and drug accumulation outside the therapeutic window.

For certain drugs, such as antibiotics, a desirable MEC can be determined. For drugs that have a narrow therapeutic range (eg, digoxin and phenytoin), there is a need to define the therapeutic minimum and maximum nontoxic plasma concentrations (MEC and MTC, respectively). In calculating a multiple-dose regimen, the desired or *target* plasma drug concentration must be related to a therapeutic response, and the multiple-dose regimen must be designed to produce plasma concentrations within the therapeutic window.

There are two main parameters that can be adjusted in developing a dosage regimen: (1) the size of the drug dose and (2) τ , the frequency of drug administration (ie, the time interval between doses).

DRUG ACCUMULATION

To calculate a multiple-dose regimen for a patient or patients, pharmacokinetic parameters are first obtained from the plasma level-time curve generated by single-dose drug studies. With these pharmacokinetic parameters and knowledge of the size of the dose and dosage interval (τ), the complete plasma level-time curve or

the plasma level may be predicted at any time after the beginning of the dosage regimen.

For calculation of multiple-dose regimens, it is necessary to decide whether successive doses of drug will have any effect on the previous dose. The principle of *superposition* assumes that early doses of drug do not affect the pharmacokinetics of subsequent doses. Therefore, the blood levels after the second, third, or *n*th dose will overlay or superimpose the blood level attained after the (n-1)th dose. In addition, the AUC = $(\int_0^{\infty} C_p dt)$ for the first dose is equal to the steady-state area between doses, that is, $(\int_{-t_2}^{t_2} C_p dt)$ as shown in Fig. 9-1.

¹ The principle of *superposition* allows the pharmacokineticist to project the plasma drug concentrationtime curve of a drug after multiple consecutive doses based on the plasma drug concentration-time curve obtained after a single dose. The basic assumptions are (1) that the drug is eliminated by first-order kinetics and (2) that the pharmacokinetics of the drug after a single dose (first dose) are not altered after taking multiple doses.

The plasma drug concentrations after multiple doses may be predicted from the plasma drug concentrations obtained after a single dose. In Table 9-1, the plasma drug concentrations from 0 to 24 hours are measured after a single dose. A constant dose of drug is given every 4 hours and plasma drug concentrations after each dose are generated using the data after the first dose. Thus, the *predicted* plasma drug concentration in the patient is the total drug



FIGURE 9-1 Simulated data showing blood levels after administration of multiple doses and accumulation of blood levels when equal doses are given at equal time intervals.

concentration obtained by adding the residual drug concentration obtained after each previous dose. The superposition principle may be used to predict drug concentrations after multiple doses of many drugs. Because the superposition principle is an overlay method, it may be used to predict drug concentrations after multiple doses given at either *equal* or *unequal* dosage intervals. For example, the plasma drug concentrations may be predicted after a drug dose is given every 8 hours, or 3 times a day before meals at 8 AM, 12 noon, and 6 PM.

There are situations, however, in which the superposition principle does not apply. In these cases, the pharmacokinetics of the drug change after multiple dosing due to various factors, including changing pathophysiology in the patient, saturation of a drug carrier system, enzyme induction, and enzyme inhibition. Drugs that follow nonlinear pharmacokinetics (see Chapter 10) generally do not have predictable plasma drug concentrations after multiple doses using the superposition principle.

If the drug is administered at a fixed dose and a fixed dosage interval, as is the case with many multiple-dose regimens, the amount of drug in the body will increase and then plateau to a mean plasma level higher than the peak $C_{\rm p}$ obtained from the initial dose (Figs. 9-1 and 9-2). When the second dose is given after a time interval shorter than the time required to "completely" eliminate the previous dose, drug accumulation will occur in the body. In other words, the plasma concentrations following the second dose will be higher than corresponding plasma concentrations immediately following the first dose. However, if the second dose is given after a time interval longer than the time required to eliminate the previous dose, drug will not accumulate (see Table 9-1).

As repetitive equal doses are given at a constant frequency, the plasma level-time curve plateaus and a steady state is obtained. At steady state, the plasma drug levels fluctuate between C_{\max}^{∞} and C_{\min}^{∞} . Once steady state is obtained, C_{\max}^{∞} and C_{\min}^{∞} are constant and remain unchanged from dose to dose. In addition, the AUC between $(\int_{t_1}^{t_2} C_p dt)$ is constant during a dosing interval at steady state (see Fig. 9-1). The C_{\max}^{∞} should always remain below the MTC. The C_{\max}^{∞}

Dose Number		Plasma Drug Concentration (µg/mL)						
	Time (h)	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6	Total
1	0	0		54 - 24 1	10 Marson		George Ste	0
	1	21.0						21.0
	2	22.3						22.3
	3	19.8						19.8
2	4	16.9	0					16.9
	5	14.3	21.0					35.3
	6	12.0	22.3					34.3
	7	10.1	19.8					29.9
3	8	8.50	16.9	0				25.4
	9	7.15	14.3	21.0				42.5
	10	6.01	12.0	22.3				40.3
	11	5.06	10.1	19.8				35.0
4	12	4.25	8.50	16.9	0			29.7
	13	3.58	7.15	14.3	21.0			46.0
	14	3.01	6.01	12.0	22.3			43.3
	15	2.53	5.06	10.1	19.8			37.5
5	16	2.13	4.25	8.50	16.9	0		31.8
	17	1.79	3.58	7.15	14.3	21.0		47.8
	18	1.51	3.01	6.01	12.0	22.3		44.8
	19	1.27	2.53	5.06	10.1	19.8		38.8
6	20	1.07	2.13	4.25	8.50	16.9	0	32.9
	21	0.90	1.79	3.58	7.15	14.3	21.0	48.7
	22	0.75	1.51	3.01	6.01	12.0	22.3	45.6
	23	0.63	1.27	2.53	5.06	10.1	19.8	39.4
	24	0.53	1.07	2.13	4.25	8.50	16.9	33.4

TABLE 9-1 Predicted Plasma Drug Concentrations for Multiple-Dose Regimen Using the Superposition Principle^a

^aA single oral dose of 350 mg was given and the plasma drug concentrations were measured for 0–24 h. The same plasma drug concentrations are assumed to occur after doses 2–6. The total plasma drug concentration is the sum of the plasma drug concentrations due to each dose. For this example, $V_D = 10 \text{ L}$, $t_{1/2} = 4 \text{ h}$, and $k_a = 1.5 \text{ h}^{-1}$. The drug is 100% bioavailable and follows the pharmacokinetics of a one-compartment open model.

208 Chapter 9

is also a good indication of drug accumulation. If a drug produces the same C_{\max}^{∞} at steady state, compared with the $(C_{n-1})_{\max}$ after the first dose, then there is no drug accumulation. If C_{\max}^{∞} is much larger than $(C_{n-1})_{\max}$, then there is significant accumulation during the multiple-dose regimen. Accumulation is affected by the elimination half-life of the drug and the dosing interval. The index for measuring drug accumulation *R* is

$$R = \frac{(C^{\infty})_{\max}}{(C_{n=1})_{\max}}$$
(9.1)

Substituting for C_{max} after the first dose and at steady state yields

$$R = \frac{D_0 / V_{\rm D} [1/(1 - e^{-k\tau})]}{D_0 / V_{\rm D}}$$
(9.2)
$$R = \frac{1}{1 - e^{-k\tau}}$$

Equation 9.2 shows that drug accumulation measured with the R index depends on the elimination constant and the dosing interval and is independent of the dose. For a drug given in repetitive oral doses, the time required to reach steady state is dependent on the elimination half-life of the drug and is independent of the size of the dose, the length of the dosing interval, and the number of doses. For example, if the dose or dosage interval of the drug is altered as shown in Fig. 9-2, the time required for the drug to reach steady state is the same, but the final steady-state plasma level changes proportionately.



FIGURE 9-2 Amount of drug in the body as a function of time. Equal doses of drug were given every 6 hours (upper curve) and every 8 hours (lower curve). k_a and k remain constant.



FIGURE 9-3 Simulated plasma drug concentration–time curves after IV infusion and oral multiple doses for a drug with an elimination half-life of 4 hours and apparent V_D of 10 L. IV infusion given at a rate of 25 mg/h, oral multiple doses are 200 mg every 8 hours, 300 mg every 12 hours, and 600 mg every 24 hours.

Furthermore, if the drug is given at the same dosing rate but as an infusion (eg, 25 mg/h), the average plasma drug concentrations will (C_{av}^{∞}) be the same but the fluctuations between C_{max}^{∞} and C_{min}^{∞} will vary (Fig. 9-3). An average steady-state plasma drug concentration is obtained by dividing the area under the curve (AUC) for a dosing period (ie, $\int_{t_1}^{t_2} C_p dt$) by the dosing interval τ , at steady state.

An equation for the estimation of the time to reach one-half of the steady-state plasma levels or the accumulation half-life has been described by van Rossum and Tomey (1968).

Accumulation
$$t_{1/2} = t_{1/2} \left(1 + 3.3 \log \frac{k_{\rm a}}{k_{\rm a} - k} \right)$$
 (9.3)

For IV administration, k_a is very rapid (approaches ∞); k is very small in comparison to k_a and can be omitted in the denominator of Equation 9.3. Thus, Equation 9.3 reduces to

Accumulation
$$t_{1/2} = t_{1/2} \left(1 + 3.3 \log \frac{k_a}{k_a} \right)$$
 (9.4)

Since $k_a/k_a = 1$ and log 1 = 0, the accumulation $t_{1/2}$ of a drug administered intravenously is the elimination $t_{1/2}$ of the drug. From this relationship, the time to reach 50% steady-state drug concentrations is dependent only on the elimination $t_{1/2}$ and not on the dose or dosage interval.

As shown in Equation 9.4, the accumulation $t_{1/2}$ is directly proportional to the elimination $t_{1/2}$. Table 9-2 gives the accumulation $t_{1/2}$ of drugs with various elimination half-lives given by multiple oral doses (see Table 9-2).

From a clinical viewpoint, the time needed to reach 90% of the steady-state plasma concentration is 3.3 times the elimination half-life, whereas the time required to reach 99% of the steady-state plasma concentration is 6.6 times the elimination half-life (Table 9-3). It should be noted from Table 9-3 that at a constant dose size, the shorter the dosage interval, the larger the dosing rate (mg/h), and the higher the steady-state drug level.

The number of doses for a given drug to reach steady state is dependent on the elimination half-life

of the drug and the dosage interval τ (see Table 9-3). If the drug is given at a dosage interval equal to the half-life of the drug, then 6.6 doses are required to reach 99% of the theoretical steady-state plasma drug concentration. The number of doses needed to reach steady state is $6.6t_{1/2}/\tau$, as calculated in the far right column of Table 9-3. As discussed in Chapter 6, Table 6-1, it takes 4.32 half-lives to reach 95% of steady state.

CLINICAL EXAMPLE

Paroxetine (Prozac) is an antidepressant drug with a long elimination half-life of 21 hours. Paroxetine is well absorbed after oral administration and has a t_{max} of about 5 hours, longer than most drugs. Slow elimination may cause the plasma curve to peak slowly. The t_{max} is affected by k and k_a , as discussed in Chapter 8. The C_{max} for paroxetine after multiple dosing of 30 mg of paroxetine for 30 days in one study ranged from 8.6 to 105 ng/mL among 15 subjects. Clinically it is important to achieve a stable steady-state level in multiple dosing that does not "underdose" or overdose the patient. The pharmacist should advise the patient to follow the prescribed dosing interval and dose as accurately as possible. Taking a dose too early or too late contributes to

Elimination Half-life (h)	Elimination Rate constant (1/h)	Absorption Rate Constant (1/h)	Accumulation Half-life (h)	
4	0.173	1.50	4.70	
8	0.0866	1.50	8.67	
12	0.0578	1.50	12.8	
24	0.0289	1.50	24.7	
4	0.173	1.00	5.09	
8	0.0866	1.00	8.99	
12	0.0578	1.00	13.0	
24	0.0289	1.00	25.0	

TABLE 9-2 Effect of Elimination Half-Life and Absorption Rate Constant on Accumulation Half-Life after Oral Administration^a

^aAccumulation half-life is calculated by Equation 8.3, and is the half-time for accumulation of the drug to 90% of the steady-state plasma drug concentration.

210 Chapter 9

Elimination Half-Life (h)	Dosage Interval, $ au(h)$	C _{max} (µg/mL)	Time for $C_{\rm av}^{\infty b}$ (h)	NO. Doses to Reach 99% Steady State
0.5	0.5	200	3.3	6.6
0.5	1.0	133	3.3	3.3
1.0	0.5	341	6.6	13.2
1.0	1.0	200	6.6	6.6
1.0	2.0	133	6.6	3.3
1.0	4.0	107	6.6	1.65
1.0	10.0	100 ^c	6.6	0.66
2.0	1.0	341	13.2	13.2
2.0	2.0	200	13.2	6.1

TABLE 9-3 Interrelation of Elimination Half-Life, Dosage Interval, Maximum PlasmaConcentration, and Time to Reach Steady-State Plasma Concentration^a

^aA single dose of 1000 mg of three hypothetical drugs with various elimination half-lives but equal volumes of distribution ($V_D = 10$ L) were given by multiple IV doses at various dosing intervals. All time values are in hours; $C_{max}^{\infty} = maximum$ steady-state concentration; ($C_{av}^{\infty b}$) = average steady-state plasma concentration; the maximum plasma drug concentration after the first dose of the drug is ($C_{n=1}$)_{max} = 100 µg/mL.

^bTime to reach 99% of steady-state plasma concentration.

cSince the dosage interval, τ_i is very large compared to the elimination half-life, no accumulation of drug occurs.

variation. Individual variation in metabolism rate can also cause variable blood levels, as discussed later in Chapter 13. The fraction (f) of the dose remaining in the body is related to the elimination constant (k) and the dosage interval (τ) as follows:

$$f = \frac{D_{\rm B}}{D_0} = e^{-k\tau} \tag{9.7}$$

REPETITIVE INTRAVENOUS INJECTIONS

The maximum amount of drug in the body following a single rapid IV injection is equal to the dose of the drug. For a one-compartment open model, the drug will be eliminated according to first-order kinetics.

$$D_{\rm B} = D_0 e^{-k\tau} \tag{9.5}$$

If τ is equal to the dosage interval (ie, the time between the first dose and the next dose), then the amount of drug remaining in the body after several hours can be determined with

$$D_{\rm B} = D_0 e^{-k\tau} \tag{9.6}$$

With any given dose, f depends on k and τ . If τ is large, f will be smaller because $D_{\rm B}$ (the amount of drug remaining in the body) is smaller.

EXAMPLES >>>

- **1.** A patient receives 1000 mg every 6 hours by repetitive IV injection of an antibiotic with an elimination half-life of 3 hours. Assume the drug is distributed according to a one-compartment model and the volume of distribution is 20 L.
 - a. Find the maximum and minimum amounts of drug in the body.
 - **b.** Determine the maximum and minimum plasma concentrations of the drug.

Solution

a. The fraction of drug remaining in the body is estimated by Equation 9.7. The concentration of the drug declines to one-half after 3 hours ($t_{1/2} =$ 3 h), after which the amount of drug will again decline by one-half at the end of the next 3 hours. Therefore, at the end of 6 hours, only one-quarter, or 0.25, of the original dose remains in the body. Thus *f* is equal to 0.25. To use Equation 9.7, we must first find the value of *k* from the $t_{1/2}$.

$$k = \frac{0.693}{t_{1/2}} = \frac{0.693}{3} = 0.231 \,\mathrm{h}^{-1}$$

The time interval τ is equal to 6 hours. From Equation 9.7,

$f = e^{-(0.231)(6)}$

f = 0.25

In this example, 1000 mg of drug is given intravenously, so the amount of drug in the body is immediately increased by 1000 mg. At the end of the dosage interval (ie, before the next dose), the amount of drug remaining in the body is 25% of the amount of drug present just after the previous dose, because f = 0.25. Thus, if the value of fis known, a table can be constructed relating the fraction of the dose in the body before and after rapid IV injection (Table 9-4).

From Table 9-4 the maximum amount of drug in the body is 1333 mg and the minimum amount of drug in the body is 333 mg. The difference between the maximum and minimum values, D_{0x} will always equal the injected dose.

$$D_{\rm max} - D_{\rm min} = D_0$$
 (9.8)

In this example,

$$1333 - 333 = 1000 \text{ mg}$$

 D_{max}^{∞} can also be calculated directly by the relationship

$$D_{\max}^{\infty} = \frac{D_0}{1-f}$$
 (9.9)

TABLE 9-4Fraction of the Dose in the Bodybefore and after Intravenous Injections of a1000-mg Dose^a

	Amount of Drug in Body			
Number of Doses	Before Dose	After Dose		
1 Sec. 1 Sugar	0	1000		
2	250	1250		
3	312	1312		
4	328	1328		
5	332	1332		
6	333	1333		
7	333	1333		
~	333	1333		

af = 0.25.

Substituting known data, we obtain

$$D_{\rm max}^{\infty} = \frac{1000}{1-0.25} = 1333 \,{\rm mg}$$

Then, from Equation 9.8,

 $D_{\min}^{\infty} = 1333 - 1000 = 333 \text{ mg}$

The average amount of drug in the body at steady state, D_{av}^{∞} , can be found by Equation 9.10 or Equation 9.11. *F* is the fraction of dose absorbed. For an IV injection, *F* is equal to 1.0.

$$D_{\rm av}^{\infty} = \frac{FD_0}{k\tau} \tag{9.10}$$

$$D_{\rm av}^{\infty} = \frac{FD_0 1.44 t_{1/2}}{\tau}$$
(9.11)

Equations 9.10 and 9.11 can be used for repetitive dosing at constant time intervals and for any route of administration as long as elimination occurs from the central compartment. Substitution of values from the example into Equation 9.11 gives

$$D_{\rm av}^{\infty} = \frac{(1)(1000)(1.44)(3)}{6} = 720 \text{ mg}$$

Since the drug in the body declines exponentially (ie, first-order drug elimination), the value D_{av}^{∞} is not the arithmetic mean of D_{max}^{∞} and D_{min}^{∞} . The limitation

of using D_{av}^{∞} is that the fluctuations of D_{max}^{∞} and D_{min}^{∞} are not known.

b. To determine the concentration of drug in the body after multiple doses, divide the amount of drug in the body by the volume in which it is dissolved. For a one-compartment model, the maximum, minimum, and steady-state concentrations of drug in the plasma are found by the following equations:

$$\Gamma_{\max}^{\infty} = \frac{D_{\max}^{\infty}}{V_{\rm D}}$$
(9.12)

$$C_{\min}^{\infty} = \frac{D_{\min}^{\infty}}{V_{\rm D}}$$
(9.13)

$$C_{\rm av}^{\infty} = \frac{D_{\rm av}^{\infty}}{V_{\rm D}}$$
(9.14)

A more direct approach to finding C_{\max}^{∞} , and C_{\min}^{∞} , is C_{∞}^{∞} :

$$C_{\max}^{\infty} = \frac{C_{\rm p}^0}{1 - e^{-k\tau}} \tag{9.15}$$

where C_p^0 is equal to D_0/V_D .

$$\mathcal{Z}_{\min}^{\infty} = \frac{C_{p}^{0} e^{-k\tau}}{1 - e^{-k\tau}}$$
(9.16)

$$C_{\rm av}^{\infty} = \frac{FD_0}{V_{\rm D}k\tau}$$
(9.17)

For this example, the values for C_{max}^{∞} , C_{min}^{∞} , and C_{av}^{∞} are 66.7, 16.7, and 36.1 μ g/mL, respectively.

As mentioned, C_{av}^{∞} is not the arithmetic mean of C_{max}^{∞} and C_{min}^{∞} because plasma drug concentration declines exponentially. The C_{av}^{∞} is equal to $[AUC]_{t_1}^{t_2}$ or $(\int_{t_1}^{t_2} C_p dt)$ for a dosage interval at steady state divided by the dosage interval τ .

$$r_{t} = \frac{[AUC]_{t_1}^{t_2}}{\tau}$$
 (9.18)

 C_{av}^{∞} gives an estimate of the mean plasma drug concentration at steady state. The C_{av}^{∞} is often the target drug concentration for optimal therapeutic effect and gives an indication as to how long this plasma drug concentration is maintained during the dosing interval (between doses). The C_{av}^{∞}

is dependent on both AUC and τ . The C_{av}^{∞} reflects drug exposure after multiple doses. Drug exposure is often related to drug safety and efficacy as discussed later in Chapter 21. For example, drug exposure is closely monitored when a cytotoxic or immunosuppressive, anticancer drug is administered during therapy. AUC may be estimated by sampling several plasma drug concentrations over time. Theoretically, AUC is superior to sampling just the C_{max} or C_{min}. For example, when cyclosporine dosing is clinically evaluated using AUC, the AUC is approximately estimated by two or three points. Dosing error is less than using AUC compared to the trough method alone (Primmett et al, 1998). In general, Cmin or trough level is more frequently used than C_{\max}^{∞} . C_{\min} is the drug concentration just before the next dose is given and is less variable than peak drug concentration, C_{\max}^{∞} . The sample time for C_{\max}^{∞} is approximated and the true C_{\max}^{∞} may not be accurately estimated. In some cases, the plasma trough level, C_{\min}^{∞} is considered by some investigators as a more reliable sample since the drug is equilibrated with the surrounding tissues, although this may also depend on other factors.

The AUC is related to the amount of drug absorbed divided by total body clearance (*Cl*), as shown in the following equation:

$$[AUC]_{t_1}^{t_2} = \frac{FD_0}{CI} = \frac{FD_0}{kV_D}$$
(9.19)

Substitution of FD_0/kV_D for AUC in Equation 9.18 gives Equation 9.17. Equation 9.17 or 9.18 can be used to obtain C_{av}^{∞} after a multiple-dose regimen regardless of the route of administration.

It is sometimes desirable to know the plasma drug concentration at any time after the administration of *n* doses of drug. The general expression for calculating this plasma drug concentration is

$$C_{\rm p} = \frac{D_0}{V_{\rm D}} \left(\frac{1 - e^{-nk\tau}}{1 - e^{-k\tau}} \right) e^{-k\tau}$$
(9.20)

where *n* is the number of doses given and *t* is the time after the *n*th dose.

At steady state, $e^{-nk\tau}$ approaches zero and Equation 9.20 reduces to

$$C_{\rm p}^{\infty} = \frac{D_{\rm o}}{V_{\rm p}} \left(\frac{1}{1 - e^{-k\tau}}\right) e^{-kt}$$
(9.21)

where C_p^{∞} is the steady-state drug concentration at time *t* after the dose.

2. The patient in the previous example received 1000 mg of an antibiotic every 6 hours by repetitive IV injection. The drug has an apparent volume of distribution of 20 L and elimination half-life of 3 hours. Calculate (a) the plasma drug concentration, C_p at 3 hours after the second dose, (b) the steady-state plasma drug concentration, C_p^{∞} at 3 hours after the last dose, (c) C_{\max}^{∞} , (d) C_{\min}^{∞} , and (e) C_{SS} .

Solution

a. The C_p at 3 hours after the second dose—use Equation 9.20 and let n = 2, t = 3 hours, and make other appropriate substitutions.

$$C_{\rm p} = \frac{1000}{20} \left(\frac{1 - e^{-(2)(0.231)(6)}}{1 - e^{-(0.231)(6)}} \right) e^{-0.231(3)}$$

$$C_{\rm p} = 31.3 \, {\rm mg/L}$$

b. The C_p^{∞} at 3 hours after the last dose—because steady state is reached, use Equation 9.21 and perform the following calculation:

$$C_{\rm p}^{\infty} = \frac{1000}{20} \left(\frac{1}{1 - e^{-0.231(6)}} \right) e^{-0.231(3)}$$
$$C_{\rm p}^{\infty} = 33.3 \text{ mg/L}$$

c. The C_{\max}^{∞} is calculated from Equation 9.15.

$$C_{\text{max}}^{\circ\circ} = \frac{1000/20}{1 - e^{-(0.231)(6)}} = 66.7 \text{ mg/L}$$

d. The C_{\min}^{∞} may be estimated as the drug concentration after the dosage interval τ , or just before the next dose.

$$C_{\min}^{\infty} = C_{\max}^{\infty} e^{-kt} = 66.7 e^{-(0.231)(6)} = 16.7 \text{ mg/L}$$

e. The C_{av}^{∞} is estimated by Equation 9.17—because the drug is given by IV bolus injections, F = 1.

$$C_{\rm av}^{\infty} = \frac{1000}{(0.231)(20)(6)} = 36.1 \, {\rm mg/L}$$

 C_{av}^{∞} is represented as C_{SS} in some references.

Problem of a Missed Dose

Equation 9.22 describes the plasma drug concentration t hours after the nth dose is administered; the doses are administered τ hours apart according to a multiple-dose regimen:

$$C_{\rm p} = \frac{D_0}{V_{\rm D}} \left(\frac{1 - e^{-nk\tau}}{1 - e^{-k\tau}} \right) e^{-kt}$$
(9.22)

Concentration contributed by the missing dose is

$$C'_{\rm p} = \frac{D_0}{V_{\rm D}} e^{-kt_{\rm miss}} \tag{9.23}$$

in which t_{miss} = time elapsed since the scheduled dose was missed. Subtracting Equation 9.23 from Equation 9.20 corrects for the missing dose as shown in Equation 9.24.

$$C_{\rm p} = \frac{D_0}{V_{\rm D}} \left[\left(\frac{1 - e^{-nk\tau}}{1 - e^{-k\tau}} \right) e^{-kt} - e^{-kt_{\rm miss}} \right]$$
(9.24)

Note: If steady state is reached (ie, either n = large or after many doses), the equation simplifies to Equation 9.25. Equation 9.25 is useful when steady state is reached.

$$C_{\rm p} = \frac{D_0}{V_{\rm D}} \left(\frac{e^{-kt}}{1 - e^{-kt}} \right) - e^{-kt_{\rm miss}}$$
(9.25)

Generally, if the missing dose is recent, it will affect the present drug level more. If the missing dose is several half-lives later (> $5t_{1/2}$), the missing dose may be omitted because it will be very small. Equation 9.24 accounts for one missing dose, but several missing doses can be subtracted in a similar way if necessary.

EXAMPLE

A cephalosporin ($k = 0.2 h^{-1}$, $V_D = 10 L$) was administered by IV multiple dosing; 100 mg was injected every 6 hours for 6 doses. What was the plasma drug concentration 4 hours after the sixth dose (ie, 40 hours later) if (**a**) the fifth dose was omitted, (**b**) the sixth dose was omitted, and (**c**) the fourth dose was omitted?

Solution

Substitute $k = 0.2 \text{ h}^{-1}$, $V_D = 10 \text{ L}$, D = 100 mg, n = 6, t = 4 hours, and $\tau = 6$ hours into Equation 9.20 and evaluate:

$$C_{\rm p} = 6.425 \, {\rm mg/L}$$

If no dose was omitted, then 4 hours after the sixth injection, C_p would be 6.425 mg/L.

a. Missing the fifth dose, its contribution must be subtracted off, $t_{miss} = 6 + 4 = 10$ hours (the time elapsed since missing the dose) using the steady-state equation:

$$C'_{\rm p} = \frac{D_{\rm o}}{V_{\rm D}} e^{-kt_{\rm miss}} = \frac{100}{10} e^{-(0.2 \times 10)}$$

Drug concentration correcting for the missing dose = 6.425 - 1.353 = 5.072 mg/L.

b. If the sixth dose is missing, $t_{miss} = 4$ hours:

$$C'_{\rm p} = \frac{D_0}{V_{\rm D}} e^{-kt_{\rm miss}} = \frac{100}{10} e^{-(0.2 \times 4)} = 4.493 \text{ mg/L}$$

Drug concentration correcting for the missing dose = 6.425 - 4.493 = 1.932 mg/L.

c. If the fourth dose is missing, $t_{miss} = 12 + 4 = 16$ hours:

$$C'_{\rm p} = \frac{D_0}{V_{\rm D}} e^{-kt_{\rm miss}} = \frac{100}{10} e^{-(0.2 \times 16)} = 0.408 \text{ mg/L}$$

The drug concentration corrected for the missing dose = 6.425 - 0.408 = 6.017 mg/L.

Note: The effect of a missing dose becomes less pronounced at a later time. A strict dose regimen compliance is advised for all drugs. With some drugs, missing a dose can have a serious effect on therapy. For example, compliance is important for the anti-HIV1 drugs such as the protease inhibitors.

Early or Late Dose Administration during Multiple Dosing

When one of the drug doses is taken earlier or later than scheduled, the resulting plasma drug concentration can still be calculated based on the principle of superposition. The dose can be treated as missing, with the late or early dose added back to take into account the actual time of dosing, using Equation 9.26.

$$C_{\rm p} = \frac{D_0}{V_{\rm D}} \left(\frac{1 - e^{-nkt}}{1 - e^{-kt}} e^{-kt} - e^{-kt_{\rm miss}} + e^{-kt_{\rm actual}} \right)$$
(9.26)

in which t_{miss} = time elapsed since the dose (late or early) is scheduled, and t_{actual} = time elapsed since the dose (late or early) is actually taken. Using a similar approach, a second missed dose can be subtracted from Equation 9.20. Similarly, a second late/early dose may be corrected by subtracting the scheduled dose followed by adding the actual dose. Similarly, if a different dose is given, the regular dose may be subtracted and the new dose added back.

EXAMPLE

Assume the same drug as above (ie, $k = 0.2 \text{ h}^{-1}$, $V_D = 10 \text{ L}$) was given by multiple IV bolus injections and that at a dose of 100 mg every 6 hours for 6 doses. What is the plasma drug concentration 4 hours after the sixth dose, if the fifth dose were given an hour late?

Substitute into Equation 9.26 for all unknowns: $k=0.2 \text{ h}^{-1}$, $V_{\text{D}}=10 \text{ L}$, D=100 mg, n=6, $\tau=4 \text{ h}$, $\tau=6 \text{ h}$, $t_{\text{miss}}=6+4=10 \text{ hours}$, $t_{\text{actual}}=9 \text{ hours}$ (taken 1 hour late, ie, 5 hours before the sixth dose).

$$C_{\rm p} = \frac{D_0}{V_{\rm D}} \left(\frac{1 - e^{-nk\tau}}{1 - e^{-k\tau}} e^{-k\tau} - e^{-kt_{\rm miss}} + e^{-kt_{\rm actual}} \right)$$
$$C_{\rm p} = 6.425 - 1.353 + 1.653 = 6.725 \, {\rm mg/L}$$

Note: 1.353 mg/L was subtracted and 1.653 mg/mL was added because the fifth dose was not given as planned, but was given 1 hour later.

INTERMITTENT INTRAVENOUS INFUSION

Intermittent IV infusion is a method of successive short IV drug infusions in which the drug is given by IV infusion for a short period of time followed by a drug elimination period, then followed by another



FIGURE 9-4 Plasma drug concentration after two doses by IV infusion. Data from Table 9-5.

short IV infusion (Fig. 9-4). In drug regimens involving short IV infusion, the drug may not reach steady state. The rationale for intermittent IV infusion is to prevent transient high drug concentrations and accompanying side effects. Many drugs are better tolerated when infused slowly over time compared to IV bolus dosing.

Administering One or More Doses by Constant Infusion: Superposition of Several IV Infusion Doses

For a continuous IV infusion (see Chapter 7):

$$C_{\rm p} = \frac{R}{Cl} (1 - e^{-kt}) = \frac{R}{kV_{\rm D}} (1 - e^{-kt}) \qquad (9.27)$$

Equation 9.27 may be modified to determine drug concentration after one or more short IV infusions for a specified time period (Equation 9.28).

$$C_{\rm p} = \frac{D}{t_{\rm inf} V_{\rm D} k} (1 - e^{-kt})$$
(9.28)

where R = rate of infusion = D/t_{inf} , D = size of infusion dose, and t_{inf} = infusion period.

After the infusion is stopped, the drug concentration post-IV infusion is obtained using the firstorder equation for drug elimination:

$$C_{\rm p} = C_{\rm stop} e^{-kt} \tag{9.29}$$

where $C_{\text{stop}} = \text{concentration}$ when infusion stops, and t = time elapsed since infusion stopped.

EXAMPLE

An antibiotic was infused with a 40-mg IV dose over 2 hours. Ten hours later, a second dose of 40 mg was infused, again over 2 hours. (a) What is the plasma drug concentration 2 hours after the start of the first infusion? (b) What is the plasma drug concentration 5 hours after the second dose infusion was started? Assume k = 0.2 h⁻¹ and $V_D =$ 10 L for the antibiotic.

Solution

The predicted plasma drug concentrations after the first and second IV infusions are shown in Table 9-5. Using the principle of superposition, the total plasma drug concentration is the sum of the residual drug concentrations due to the first IV infusion (column 3) and the drug concentrations due to the second IV infusion (column 4). A graphical representation of these data is shown in Fig. 9-4.

a. The plasma drug concentration at 2 hours after the first IV infusion starts is calculated from Equation 9.28.

$$C_{\rm p} = \frac{40/2}{10 \times 0.2} (1 - e^{-0.2/2}) = 3.30 \text{ mg/L}$$

b. From Table 9-5, the plasma drug concentration at 15 hours (ie, 5 hours after the start of the second IV infusion) is 2.06 μ g/mL. At 5 hours after the second IV infusion starts, the plasma drug concentration is the sum of the residual plasma drug concentrations from the first 2-hour infusion according to first-order elimination and the residual plasma drug concentrations from the second 2-hour IV infusion as shown in the following scheme:

← 10 ł	nours —	← 10 hours →		
First infusion	Stopped (no infusion	Second infusion	Stopped (no infusion	
for 2 hours	for 8 hours)	for 2 hours	for 8 hours)	

The plasma drug concentration is calculated using the first-order elimination equation, where C_{stop} is the plasma drug concentration at the stop of the 2-hour IV infusion.

216 Chapter 9

ande Manarata a Ula To costa branata seas	Time(h)	Plasma Drug Concentration after Infusion 1	Plasma Drug Concentration after Infusion 2	Total Plasma Drug Concentration
Infusion 1 begins	0	0		0
	1	1.81		1.81
Infusion 1 stopped	strong 2 and the	3.30		3.30
	3	2.70		2.70
	4	2.21		2.21
	5	1.81		1.81
	6	1.48		1.48
	. 7	1.21		1.21
	8	0.99		0.99
	9	0.81		0.81
Infusion 2 begins	10	0.67	0	0.67
	11	0.55	1.81	2.36
Infusion 2 stopped	12	0.45	3.30	3.74
	13	0.37	2.70	3.07
	14	0.30	2.21	2.51
	15	0.25	1.81	2.06

TABLE 9-5 Drug Concentration after Two Intravenous Infusions^a

^aDrug is given by a 2-hour infusion separated by a 10-hour drug elimination interval. All drug concentrations are in μ g/mL. The declining drug concentration after the first infusion dose and the drug concentration after the second infusion dose give the total plasma drug concentration.

The plasma drug concentration after the completion of the first IV infusion when t = 15 hours is

$$C_{\rm p} = C_{\rm stop} e^{-kt} = 3.30 e^{-0.2 \times 15} = 0.25 \ \mu g/L$$

The plasma drug concentration 5 hours after the second IV infusion is

$$C_{\rm p} = C_{\rm stop} e^{-kt} = 3.30 e^{-0.2 \times 3} = 1.81 \,\mu {\rm g/mL}$$

The total plasma drug concentration 5 hours after the start of the second IV infusion is

CLINICAL EXAMPLE

Gentamicin sulfate was given to an adult male patient (57 years old, 70 kg) by intermittent IV infusions. One-hour IV infusions of 90 mg of gentamicin was given at 8-hour intervals. Gentamicin clearance is similar to creatinine clearance and was estimated as 7.2 L/h with an elimination half-life of 3 hours.

- **a.** What is the plasma drug concentration after the first IV infusion?
- **b.** What is the peak plasma drug concentration, C_{max} , and the trough plasma drug concentration, C_{\min} , at steady state?

Solution

a. The plasma drug concentration directly after the first infusion is calculated from Equation 9.27, where R = 90 mg/h, Cl = 7.2 L/h, and k = 0.231 h⁻¹. The time for infusion, t_{int} is 1 hour.

$$C_{\rm p} = \frac{90}{7.2} (1 - e^{-(0.231)(1)}) = 2.58 \text{ mg/L}$$

b. The C_{max}^{∞} at steady state may be obtained from Equation 9.30.

$$C_{\max}^{\infty} = \frac{R(1 - e^{-kt_{\inf}})}{Cl} \frac{1}{(1 - e^{-kt})}$$
(9.30)

where C_{max} is the peak drug concentration following the *n*th infusion, at steady state, t_{inf} is the time period of infusion, and τ is the dosage interval. The term $1/(1 - e^{-k\tau})$ is the accumulation factor for repeated drug administration. Substitution in Equation 9.30 gives

$$C_{\max}^{\infty} = \frac{90(1 - e^{-(0.231)(1)})}{7.2} \times \frac{1}{(1 - e^{-(0.231)(8)})}$$

= 3.06 mg/L

The plasma drug concentration C_p^{∞} at any time *t* after the last infusion ends when steady state is obtained by Equation 9.31 and assumes that plasma drug concentrations decline according to first-order elimination kinetics.

$$C_{\rm p}^{\infty} = \frac{R(1 - e^{-kt_{\rm inf}})}{Cl} \times \frac{1}{(1 - e^{-kt})} \times e^{-k(t)}$$
(9.31)

where t_{inf} is the time for infusion and *t* is the time period after the end of the infusion.

The trough plasma drug concentration, C_{\min}^{∞} , at steady state is the drug concentration just before the start of the next IV infusion or after a dosage interval equal to 8 hours after the last infusion stopped. Equation 9.31 can be used to determine the plasma drug concentration at any time after the last infusion is stopped (after steady state has been reached).

$$C_{\min}^{\infty} = \frac{90(1 - e^{-(0.231)(1)})}{7.2} \times \frac{e^{-(0.231)(8)}}{(1 - e^{-(0.231)(8)})}$$
$$= 0.48 \text{ mg/L}$$

ESTIMATION OF *k* AND *V*_D OF AMINOGLYCOSIDES IN CLINICAL SITUATIONS

As illustrated above, antibiotics are often infused intravenously by multiple doses, so it is desirable to adjust the recommended starting dose based on the patient's individual k and $V_{\rm D}$ values. According to Sawchuk and Zaske (1976), individual parameters for aminoglycoside pharmacokinetics may be determined in a patient by using a limited number of plasma drug samples taken at appropriate time intervals. The equation was simplified by replacing an elaborate model with the one-compartment model to describe drug elimination and appropriately avoiding the distributive phase. The plasma sample should be collected 15-30 minutes postinfusion (with infusion lasting about 60 minutes) and, in patients with poor renal function, 1-2 hours postinfusion, to allow adequate tissue distribution. The second and third blood samples should be collected about 2-3 halflives later, in order to get a good estimation of the slope. The data may be determined graphically or by regression analysis using a scientific calculator or computer program.

$$V_{\rm D} = \frac{R(1 - e^{-kt_{\rm inf}})}{[C_{\rm max}^{\infty} - C_{\rm min}^{\infty} e^{-kt_{\rm inf}}}$$
(9.32)

The dose of aminoglycoside is generally fixed by the desirable peak, C_{max}^{∞} , and trough plasma concentration, C_{min}^{∞} . For example, C_{max}^{∞} for gentamicin may be set at 6–10 µg/mL with the steady-state trough level, C_{min}^{∞} , generally about 0.5–2 µg/mL, depending on the severity of the infection and renal considerations. The upper range is used only for life-threatening infections. The infusion rate for any desired peak drug concentration may be calculated using Equation 9.33.

$$R = \frac{V_{\rm D} k C_{\rm max}^{\infty} (1 - e^{-k\tau})}{(1 - e^{-kt_{\rm inf}})}$$
(9.33)

The dosing interval τ between infusions may be adjusted to obtain a desired concentration.

Frequently Asked Questions

- Is the drug accumulation index (R) applicable to any drug given by multiple doses or only to drugs that are eliminated slowly from the body?
- What are the advantages/disadvantages for giving a drug by a constant IV infusion, intermittent IV infusion, or multiple IV bolus injections? What drugs would most likely be given by each route of administration? Why?
- Why is the accumulation index, R, not affected by the dose or clearance of a drug? Would it be possible for a drug with a short half-life to have R much greater than 1?

MULTIPLE-ORAL-DOSE REGIMEN

Figures 9-1 and 9-2 present typical cumulation curves for the concentration of drug in the body after multiple oral doses given at a constant dosage interval. The plasma concentration at any time during an oral or extravascular multiple-dose regimen, assuming a one-compartment model and constant doses and dose interval, can be determined as follows:

$$C_{\rm p} = \frac{Fk_{\rm a}D_0}{V_{\rm D}(k-k_{\rm a})} \left[\left(\frac{1-e^{-nk_{\rm a}\tau}}{1-e^{-k_{\rm a}\tau}} \right) e^{-k_{\rm a}t} - \left(\frac{1-e^{-nk\tau}}{1-e^{-k\tau}} \right) e^{-kt} \right]$$

where n = number of doses, $\tau =$ dosage interval, F = fraction of dose absorbed, and t = time after administration of n doses.

The mean plasma level at steady state, C_{av}^{∞} , is determined by a similar method to that employed for repeat IV injections. Equation 9.17 can be used for finding C_{av}^{∞} for any route of administration.

$$C_{\rm av}^{\infty} = \frac{FD_0}{V_{\rm D}k\tau} \tag{9.17}$$

Because proper evaluation of F and V_D requires IV data, the AUC of a dosing interval at steady state may be substituted in Equation 9.17 to obtain

$$C_{\rm av}^{\infty} = \frac{\int_0^{\infty} C_{\rm p} dt}{\tau} = \frac{[\rm AUC]_0^{\infty}}{\tau}$$
(9.35)

One can see from Equation 9.17 that the magnitude of C_{av}^{∞} is directly proportional to the size of the dose and the extent of drug absorbed. Furthermore, if the dosage interval (τ) is shortened, then the value for C_{av}^{∞} will increase. The C_{av}^{∞} will be predictably higher for drugs distributed in a small V_D (eg, plasma water) or that have long elimination half-lives than for drugs distributed in a large V_D (eg, total body water) or that have very short elimination half-lives. Because body clearance (Cl_T) is equal to kV_D , substitution into Equation 9.17 yields

$$C_{\rm av}^{\infty} = \frac{FD_0}{Cl_{\rm T}\tau} \tag{9.36}$$

Thus, if Cl_{T} decreases, C_{av}^{∞} will increase.

The C_{av}^{∞} does not give information concerning the fluctuations in plasma concentration (C_{max}^{∞} and C_{min}^{∞}). In multiple-dose regimens, C_p at any time can be obtained using Equation 9.34, where n = nth dose. At steady state, the drug concentration can be determined by letting n equal infinity. Therefore, $e^{-nk\tau}$ becomes approximately equal to zero and Equation 9.22 becomes

$$C_{\rm p}^{\infty} = \frac{k_a F D_0}{V_{\rm D}(k_{\rm a} - k)} \left[\left(\frac{1}{1 - e^{-k\tau}} \right) e^{-kt'} - \left(\frac{1}{1 - e^{k_{\rm a}\tau}} \right) e^{-k_{\rm a}t} \right]$$
(9.37)

The maximum and minimum drug concentrations $(C_{\max}^{\infty} \text{ and } C_{\min}^{\infty})$ can be obtained with the following equations:

$$C_{\max}^{\infty} = \frac{FD_0}{V_{\rm D}} \left(\frac{1}{1 - e^{-k\tau}} \right) e^{-kt_{\rm p}}$$
(9.38)

$$C_{\min}^{\infty} = \frac{k_{a}FD_{0}}{V_{D}\left(k_{a}-k\right)} \left(\frac{1}{1-e^{-k\tau}}\right) e^{-k\tau}$$
(9.39)

The time at which maximum (peak) plasma concentration (or t_{max}) occurs following a single oral dose is

$$t_{\max} = \frac{2.3}{k_a - k} \log \frac{k_a}{k}$$
(9.40)

whereas the peak plasma concentration, t_p , following multiple doses is given by Equation 9.41.

$$t_{\rm p} = \frac{1}{k_{\rm a} - k} \ln \left[\frac{k_{\rm a} (1 - e^{-k\tau})}{k(1 - e^{-k_{\rm a}\tau})} \right]$$
(9.41)

Large fluctuations between C_{max}^{∞} and C_{min}^{∞} can be hazardous, particularly with drugs that have a narrow therapeutic index. The larger the number of divided doses, the smaller the fluctuations in the plasma drug concentrations. For example, a 500-mg dose of drug

given every 6 hours will produce the same C_{av}^{∞} value as a 250-mg dose of the same drug given every 3 hours, while the C_{max}^{∞} and C_{min}^{∞} fluctuations for the latter dose will be decreased by one-half (see Fig. 9-3). With drugs that have a narrow therapeutic index, the dosage interval should not be longer than the elimination half-life.

EXAMPLE 🏲 🏲 |

An adult male patient (46 years old, 81 kg) was given 250 mg of tetracycline hydrochloride orally every 8 hours for 2 weeks. From the literature, tetracycline hydrochloride is about 75% bioavailable and has an apparent volume of distribution of 1.5 L/kg. The elimination half-life is about 10 hours. The absorption rate constant is 0.9 h⁻¹. From this information, calculate (a) C_{max} after the first dose, (b) C_{min} after the first dose, (c) plasma drug concentration C_p at 4 hours after the seventh dose, (d) maximum plasma drug concentration at steady state, C_{max}^{∞} , (e) minimum plasma drug concentration at steady state, C_{min}^{∞} , and (f) average plasma drug concentration at steady state, C_{ax}^{∞} .

Solution

 a. C_{max} after the first dose occurs at t_{max}—therefore, using Equation 9.40,

$$t_{\max} = \frac{2.3}{0.9 - 0.07} \log\left(\frac{0.9}{0.07}\right)$$
$$t_{\max} = 3.07$$

Then substitute t_{max} into the following equation for a single oral dose (one-compartment model) to obtain C_{max} .

$$C_{\max} = \frac{FD_0k_a}{V_D(k_a - k)} (e^{-kt_{\max}} - e^{-k_a t_{\max}})$$
$$C_{\max} = \frac{(0.75)(250)(0.9)}{(121.5)(0.9 - 0.07)} (e^{-0.07(3.07)} - e^{-0.9(3.07)})$$

 $C_{max} = 1.28 \text{ mg/L}$

b. C_{min} after the first dose occurs just before the administration of the next dose of drug—therefore, set t = 8 hours and solve for C_{min} .

$$C_{\min} = \frac{(0.75)(250)(0.9)}{(121.5)(0.9-0.07)} (e^{-0.07(8)} - e^{-0.9(8)})$$

$$C_{min} = 0.95 mg/L$$

c. C_p at 4 hours after the seventh dose may be calculated using Equation 9.34, letting n = 7, t = 4, $\tau = 8$, and making the appropriate substitutions.

$$C_{p} = \frac{(0.75)(250)(0.9)}{(121.5)(0.07 - 0.9)} \times \left[\left(\frac{1 - e^{-(7)(0.9)(8)}}{1 - e^{-0.9(8)}} \right) e^{-0.9(4)} - \left(\frac{1 - e^{-(7)(0.07)(8)}}{1 - e^{-(0.07)(8)}} \right) e^{-0.07(4)} \right]$$

$$C_{p} = 2.86 \text{ mg/L}$$

d. C_{max}^{∞} at steady state: t_p at steady state is obtained from Equation 9.41.

$$t_{p} = \frac{1}{k_{a} - k} \ln \left[\frac{k_{a}(1 - e^{-k\tau})}{k(1 - e^{-k_{a}\tau})} \right]$$
$$t_{p} = \frac{1}{0.9 - 0.07} \ln \left[\frac{0.9(1 - e^{-(0.07)(8)})}{0.07(1 - e^{-(0.9)(8)})} \right]$$
$$t_{p} = 2.05 \text{ hours}$$

Then C_{\max}^{∞} is obtained using Equation 9.38.

$$C_{\max}^{\infty} = \frac{0.75(250)}{121.5} \left(\frac{1}{1 - e^{-0.07(8)}} \right) e^{-0.07(2.05)}$$

e. C_{\min}^{∞} at steady state is calculated from Equation 9.39.

$$C_{\min}^{\infty} = \frac{(0.9)(0.75)(250)}{(121.5)(0.9 - 0.07)} \left(\frac{1}{1 - e^{-0.07(8)}}\right) e^{-(0.7)(8)}$$

 $C_{\rm max}^{\infty} = 2.23 \text{ mg/L}$

f. C_{av}^{∞} at steady state is calculated from Equation 9.17.

$$C_{\rm av}^{\infty} = \frac{(0.75)(250)}{(121.5)(0.07)(8)}$$
$$C_{\rm av}^{\infty} = 2.76 \text{ mg/L}$$

LOADING DOSE

Since extravascular doses require time for absorption into the plasma to occur, therapeutic effects are delayed until sufficient plasma concentrations are achieved. To reduce the onset time of the drug—that is, the time it takes to achieve the minimum effective concentration (assumed to be equivalent to the C_{av}^{∞})—a loading (priming) or initial dose of drug is given. The main objective of the loading dose is to achieve desired plasma concentrations, C_{av}^{∞} , as quickly as possible. If the drug follows one-compartment pharmacokinetics, then in theory, steady state is also achieved immediately following the loading dose. Thereafter, a maintenance dose is given to maintain C_{av}^{∞} and steady state so that the therapeutic effect is also maintained. In practice, a loading dose may be given as a bolus dose or a short-term loading IV infusion.

As discussed earlier, the time required for the drug to accumulate to a steady-state plasma level is dependent mainly on its elimination half-life. The time needed to reach 90% of C_{av}^{∞} is approximately 3.3 half-lives, and the time required to reach 99% of C_{av}^{∞} is equal to approximately 6.6 half-lives. For a drug with a half-life of 4 hours, it will take approximately 13 and 26 hours to reach 90% and 99% of C_{av}^{∞} , respectively.

For drugs absorbed rapidly in relation to elimination $(k_a \gg k)$ and that are distributed rapidly, the loading dose D_L can be calculated as follows:

$$\frac{D_{\rm L}}{D_0} = \frac{1}{(1 - e^{-k_{\rm a}\tau})(1 - e^{-k\tau})} \tag{9.42}$$

For extremely rapid absorption, as when the product of $k_{\rm a}\tau$ is large or in the case of IV infusion, $e^{-k_{\rm a}\tau}$ becomes approximately zero and Equation 9.42 reduces to

$$\frac{D_{\rm L}}{D_0} = \frac{1}{1 - e^{-k\tau}} \tag{9.43}$$

The loading dose should approximate the amount of drug contained in the body at steady state. The dose ratio is equal to the loading dose divided by the maintenance dose.

Dose ratio =
$$\frac{D_{\rm L}}{D_0}$$
 (9.44)

As a general rule of thumb, if the selected dosage interval is equal to the drug's elimination half-life, then the dose ratio calculated from Equation 9.44 should be equal to 2.0. In other words, the loading dose will be equal to double the initial drug dose. Figure 9-5 shows the plasma level-time curve for dosage regimens with equal maintenance doses but



FIGURE 9-5 Concentration curves for dosage regimens with equal maintenance doses (*D*) and dosage intervals (τ) and different dose ratios. (From Kruger-Thiemer, 1968, with permission.)

different loading doses. A rapid approximation of loading dose, $D_{\rm I}$, may be estimated from

$$D_{\rm L} = \frac{V_{\rm D} C_{\rm av}^{\infty}}{(S)(F)} \tag{9.45}$$

where C_{av}^{∞} is the desired plasma drug concentration, *S* is the salt form of the drug, and *F* is the fraction of drug bioavailability.

Equation 9.45 assumes very rapid drug absorption from an immediate-release dosage form. The $D_{\rm L}$ calculated by this method has been used in clinical situations for which only an approximation of the $D_{\rm L}$ is needed.

These calculations for loading doses are not applicable to drugs that demonstrate multicompartment kinetics. Such drugs distribute slowly into extravascular tissues, and drug equilibration and steady state may not occur until after the apparent plateau is reached in the vascular (central) compartment.

DOSAGE REGIMEN SCHEDULES

Predictions of steady-state plasma drug concentrations usually assume the drug is given at a constant dosage interval throughout a 24-hour day. Very often,



FIGURE 9-6 Plasma level-time curve for theophylline given in doses of 160 mg 3 times a day. Dashed lines indicate the therapeutic range. (From Niebergall et al, 1974, with permission.)

however, the drug is given only during the waking hours (Fig. 9-6). Niebergall et al (1974) discussed the problem of scheduling dosage regimens and particularly warned against improper timing of the drug dosage. For drugs with a narrow therapeutic index such as theophylline (Fig. 9-6), large fluctuation between the maximum and minimum plasma levels are undesirable and may lead to subtherapeutic plasma drug concentrations and/or to high, possibly toxic, drug concentrations. These wide fluctuations occur if larger doses are given at wider dosage intervals (see Fig. 9-3). For example, Fig. 9-7 shows



FIGURE 9-7 Plasma level–time curve for procainamide given in an initial dose of 1.0 g followed by doses of 0.5 g 4 times a day. Dashed lines indicate the therapeutic range. (From Niebergall et al, 1974, with permission.)

procainamide given with a 1.0-g loading dose on the first day followed by maintainence doses of 0.5-g four times a day. On the second, third, and subsequent days, the procainamide plasma levels did not reach the therapeutic range until after the second dose of drug.

Ideally, drug doses should be given at evenly spaced intervals. However, to improve patient compliance, dosage regimens may be designed to fit with the lifestyle of the patient. For example, the patient is directed to take a drug such as amoxicillin four times a day (QID), before meals and at bedtime, for a systemic infection. This dosage regimen will produce unequal dosage intervals during the day, because the patient takes the drug before breakfast, at 0800 hours (8 AM); before lunch, at 1200 hours (12 noon); before dinner, at 1800 hours (6 PM); and before bedtime, at 2300 hours (11 PM). For these drugs, evenly spaced dosage intervals are not that critical to the effectiveness of the antibiotic as long as the plasma drug concentrations are maintained above the minimum inhibitory concentration (MIC) for the microorganism. In some cases, a drug may be given at a larger dose allowing for a longer duration above MIC if fluctuation is less critical. In Augmentin Bid-875 (amoxicillin/clavulanate tablets), the amoxicillin/ clavulanate tablet is administered twice daily.

Patient compliance with multiple-dose regimens may be a problem for the patient in following the prescribed dosage regimen. Occasionally, a patient may miss taking the drug dose at the prescribed dosage interval. For drugs with long elimination halflives (eg, levothyroxine sodium or oral contraceptives), the consequences of one missed dose are minimal, since only a small fraction of drug is lost between daily dosing intervals. The patient should either take the next drug dose as soon as the patient remembers or continue the dosing schedule starting at the next prescribed dosing period. If it is almost time for the next dose, then the skipped dose should not be taken and the regular dosing schedule should be maintained. Generally, the patient should not double the dose of the medication. For specific drug information on missed doses, USP DI II, Advice for the Patient, published annually by the United States Pharmacopeia, is a good source of information.

The problems of widely fluctuating plasma drug concentrations may be prevented by using a controlled-release formulation of the drug, or a drug in the same therapeutic class that has a long elimination half-life. The use of extended-release dosage forms allows for less frequent dosing and prevents undermedication between the last evening dose and the first morning dose. Extended-release drug products may improve patient compliance by decreasing the number of doses within a 24-hour period that the patient needs to take. Patients generally show better compliance with a twice-a-day (BID) dosage regimen compared to a three-times-a-day (TID) dosage schedule.

CLINICAL EXAMPLE

Bupropion hydrochloride (Wellbutrin) is a noradrenergic/dopaminergic antidepressant. Jefferson et al, 2005, have reviewed the pharmacokinetic properties of bupropion and its various various formulations and clinical applications, the goal of which is optimization of major depressive disorder treatment. Bupropion hydrochloride is available in three oral formulations. The immediate-release (IR) tablet is given three times a day, the sustained-release tablet (Wellbutrin SR) is given twice a day, and the extended-release tablet (Wellbutrin XL) is given once a day.

The total daily dose was 300 mg bupropion HCl. The area under the curve, AUC, for each dose treatment was similar showing that the formulations were bioequivalent based on extent of absorption. The fluctuations between peak and trough levels were greatest for the IR product given three times a day and least for the once-a-day XL product. According to the manufacturer, all three dosage regimens provide equivalent clinical efficacy. The advantage of the extended-release product is that the patient needs only to take the drug once a day. Often, immediate-release drug products are less expensive compared to an extended-release drug product. In this case, the fluctuating plasma drug levels for buproprion IR tablet given three times a day are not a safety issue and the tablet is equally efficacious as the 150-mg SR tablet given twice a day or the 300-mg XL tablet given once a day. The patient may also consider the cost of the medication.

PRACTICE PROBLEMS

1. Patient C.S. is a 35-year-old man weighing 76.6 kg. The patient is to be given multiple IV bolus injections of an antibiotic every 6 hours. The effective concentration of this drug is 15 μ g/mL. After the patient is given a single IV dose, the elimination half-life for the drug is determined to be 3.0 hours and the apparent $V_{\rm D}$ is 196 mL/kg. Determine a multiple IV dose regimen for this drug (assume drug is given every 6 hours).

Solution

$$C_{\rm av}^{\infty} = \frac{FD_0}{V_{\rm D}k\tau}$$

For IV dose, F = 1,

$$D_0 = (15 \ \mu g/mL) \left(\frac{0.693}{3 \ h}\right) (196 \ mL/kg) (6 \ h)$$

 $D_0 = 4.07 \text{ mg/kg}$ every 6 hours

Since patient C.S. weighs 76.6 kg, the dose should be as shown:

$$D_0 = (4.07 \text{ mg/kg})(76.6 \text{ kg})$$

 $D_0 = 312 \text{ mg every 6 hours}$

After the condition of this patient has stabilized, the patient is to be given the drug orally for convenience of drug administration. The objective is to design an oral dosage regimen that will produce the same steady-state blood level as the multiple IV doses. The drug dose will depend on the bioavailability of the drug from the drug product, the desired therapeutic drug level, and the dosage interval chosen. Assume that the antibiotic is 90% bioavailable and that the physician would like to continue oral medication every 6 hours.

The average or steady-state plasma drug level is given by

$$C_{\rm av}^{\infty} = \frac{FD_0}{V_{\rm D}k\tau}$$
$$D_0 = \frac{(15 \ \mu\text{g/mL})(193 \ \text{mL/kg})(0.693)(6 \ \text{h})}{(0.9)(3 \ \text{h})}$$

 $D_0 = 454 \text{ mg/kg}$

Because patient C.S. weighs 76.6 kg, he should be given the following dose:

 $D_0 = (4.54 \text{ mg/kg})(76.6 \text{ kg})$ $D_0 = 348 \text{ mg every 6 hours}$ For drugs with equal absorption but slower absorption rates (F is the same but k_a is smaller), the initial dosing period may show a lower blood level; however, the steady-state blood level will be unchanged.

- 2. In practice, drug products are usually commercially available in certain specified strengths. Using the information provided in the preceding problem, assume that the antibiotic is available in 125-, 250-, and 500-mg tablets. Therefore, the pharmacist or prescriber must now decide which tablets are to be given to the patient. In this case, it may be possible to give the patient 375 mg (eg, one 125-mg tablet and one 250-mg tablet) every 6 hours. However, the C_{av}^{∞} should be calculated to determine if the plasma level is approaching a toxic value. Alternatively, a new dosage interval might be appropriate for the patient. It is very important to design the dosage interval and the dose to be as simple as possible, so that the patient will not be confused and will be able to comply with the medication program properly.
 - **a.** What is the new C_{av}^{∞} if the patient is given 375 mg every 6 hours?

Solution

$$C_{\rm av}^{\infty} = \frac{(0.9)(375,000)(3)}{(196)(76.6)(6)(0.693)}$$
$$C_{\rm av}^{\infty} = 16.2 \ \mu \rm{g/mL}$$

Because the therapeutic objective was to achieve a minimum effective concentration (MEC) of $15 \mu g/mL$, a value of 16.2 $\mu g/mL$ is reasonable.

b. The patient has difficulty in distinguishing tablets of different strengths. Can the patient take a 500-mg dose (eg, two 250-mg tablets)?

Solution

The dosage interval (τ) for the 500-mg tablet would have to be calculated as follows:

$$\tau = \frac{(0.9)(500,000)(3)}{(196)(76.6)(15)(0.693)}$$

$$\tau = 8.63 \text{ h}$$

c. A dosage interval of 8.63 hours is difficult to remember. Is a dosage regimen of 500 mg every 8 hours reasonable?

Solution

$$C_{\rm av}^{\infty} = \frac{(0.9)(500,000)(3)}{(196)(76.6)(8)(0.693)}$$
$$C_{\rm av}^{\infty} = 16.2 \ \mu {\rm g/mL}$$

Notice that a larger dose is necessary if the drug is given at longer intervals.

In designing a dosage regimen, one should consider a regimen that is practical and convenient for the patient. For example, for good compliance, the dosage interval should be spaced conveniently for the patient. In addition, one should consider the commercially available dosage strengths of the prescribed drug product.

The use of Equation 9.17 to estimate a dosage regimen initially has wide utility. The C_{av}^{∞} is equal to the dosing rate divided by the total body clearance of the drug in the patient:

$$C_{\rm av}^{\infty} = \frac{FD_0}{\tau} \frac{1}{Cl_{\rm T}} \tag{9.47}$$

where FD_0/τ is equal to the dosing rate *R*, and $1/Cl_T$ is equal to $1/kV_D$.

In designing dosage regimens, the dosing rate D_0/τ is adjusted for the patient's drug clearance to obtain the desired C_{av}^{∞} . For an IV infusion, the zero-order rate of infusion (*R*) is used to obtain the desired steady-state plasma drug concentration C_{SS} . If *R* is substituted for FD_0/τ in Equation 9.47, then the following equation for estimating C_{SS} after an IV infusion is obtained:

$$C_{\rm ss} = \frac{R}{Cl_{\rm T}} \tag{9.48}$$

From Equations 9.47 and 9.48, all dosage schedules having the same dosing rate D_0/τ , or *R*, will have the same C_{av}^{∞} or C_{SS} , whether the drug is given by multiple doses or by IV infusion. For example, dosage schedules of 100 mg every 4 hours, 200 mg every 8 hours, 300 mg every 12 hours, and 600 mg every 24 hours will yield the same C_{av}^{∞} in the patient. An IV infusion rate of 25 mg/h in the same patient will give a C_{SS} equal to the C_{av}^{∞} obtained with the multiple-dose schedule (see Fig. 9-3; Table 9-6).

Dosing Schedule			Steady-State Drug Concentration (µg/mL)		
Dose (mg)	1 (h)	Dosing Rate, D ₀ /τ (mg/h)	C _{max}	C _{av} ⊂ the solid set	C _{min}
-		25 ^b	14.5	14.5	14.5
100	4	25	16.2	14.5	11.6
200	8	25	20.2	14.5	7.81
300	12	25	25.3	14.5	5.03
600	24	25	44.1	14.5	1.12
400	8	50	40.4	28.9	15.6
600	8	75	60.6	43.4	23.4

TABLE 9-6 Effect of Dosing Schedule on Predicted Steady-State Plasma Drug Concentrations^a

^aDrug has an elimination half-life of 4 hours and an apparent $V_{\rm D}$ of 10 L.

^bDrug given by IV infusion. The first-order absorption rate constant k_a is 1.2 h⁻¹ and the drug follows a one-compartment open model.

Frequently Asked Questions

- Why is the steady-state peak plasma drug concentration measured sometime after an IV dose is given in a clinical situation?
- Why is the C_{min} value at steady state less variable than the C_{max} value at steady state?
- Is it possible to take a single blood sample to measure the C_{av} value at steady state?

CHAPTER SUMMARY

The purpose of giving a loading dose is to achieve desired (therapeutic) plasma concentrations as quickly as possible. For a drug with long elimination half-life, it may take a long time (several half-lives) to achieve steady-state levels. The loading dose must be calculated appropriately based on pharmacokinetic parameters to avoid overdosing. When several doses are administered for a drug with linear kinetics, drug accumulation may occur according to the principle of superposition. Superposition allows the derivation of equations that predict the plasma drug peak and trough concentrations of a drug at steady state and the theoretical drug concentrations at any time after the dose is given. The principle of superposition is used to examine the effect of an early, late, or missing dose on steady-state drug concentration.

 C_{\max}^{∞} , C_{\min}^{∞} , and C_{av}^{∞} are useful parameters for monitoring the safety and efficacy of a drug during

multiple dosing. A clinical example of multiple dosing using short, intermittent intravenous infusions has been applied to the aminoglycosides and is based on pharmacokinetics and clinical factors for safer dosing. The index for measuring drug accumulation during multiple dosing, R, is related to the dosing interval and the half-life of the drug, but not the dose. This parameter compares the steady-state concentration with drug concentration after the initial dose. The plasma concentration at any time during an oral or extravascular multiple-dose regimen, for a one-compartment model and constant doses and dose interval, is dependent on n = number of doses, τ = dosage interval, F = fraction of dose absorbed, and t = time after administration of n doses.

$$C_{\rm p} = \frac{Fk_{\rm a}D_0}{V_{\rm D}(k-k_{\rm a})} \left[\left(\frac{1-e^{-nk_{\rm a}\tau}}{1-e^{-k_{\rm a}\tau}} \right) e^{-k_{\rm a}\tau} - \left(\frac{1-e^{-nk_{\rm a}\tau}}{1-e^{-k\tau}} \right) e^{-kt} \right]$$

The trough steady-state concentration after multiple oral dosing is

$$C_{\min}^{\infty} = \frac{k_{\rm a} F D_0}{V_{\rm D}(k_{\rm a} - k)} \left(\frac{1}{1 - e^{-k\tau}}\right) e^{-k\tau}$$

LEARNING QUESTIONS

- Gentamicin has an average elimination halflife of approximately 2 hours and an apparent volume of distribution of 20% of body weight. It is necessary to give gentamicin, 1 mg/kg every 8 hours by multiple IV injections, to a 50-kg woman with normal renal function. Calculate (a) C_{max}, (b) C_{min}, and (c) C[∞]_{av}.
- 2. A physician wants to give theophylline to a young male asthmatic patient (age 29 years, 80 kg). According to the literature, the elimination half-life for theophylline is 5 hours and the apparent $V_{\rm D}$ is equal to 50% of the body weight. The plasma level of theophylline required to provide adequate airway ventilation is approximately 10 μ g/mL.
 - a. The physician wants the patient to take medication every 6 hours around the clock. What dose of theophylline would you recommend (assume theophylline is 100% bioavailable)?
 - **b.** If you were to find that theophylline is available to you only in 225-mg capsules, what dosage regimen would you recommend?
- 3. What pharmacokinetic parameter is most important in determining the time at which the steady-state plasma drug level (C_{av}^{∞}) is reached?
- 4. Name two ways in which the fluctuations of plasma concentrations (between C_{\max}^{∞} and C_{\min}^{∞}) can be minimized for a person on a multiple-dose drug regimen without altering the $C_{\alpha y}^{\infty}$.
- 5. What is the purpose of giving a loading dose?
- 6. What is the loading dose for an antibiotic ($k = 0.23 \text{ h}^{-1}$) with a maintenance dose of 200 mg every 3 hours?
- 7. What is the main advantage of giving a potent drug by IV infusion as opposed to multiple IV injections?
- **8.** A drug has an elimination half-life of 2 hours and a volume of distribution of 40 L. The drug

The relationship between average steady-state concentration, the AUC, and dosing interval is

$$C_{\rm av}^{\infty} = \frac{\int_0^{\infty} C_{\rm p} dt}{\tau} = \frac{[\rm AUC]_0^{\infty}}{\tau}$$

This parameter is a good measure of drug exposure.

is given at a dose of 200 mg every 4 hours by multiple IV bolus injections. Predict the plasma drug concentration at 1 hour after the third dose.

- 9. The elimination half-life of an antibiotic is 3 hours and the apparent volume of distribution is 20% of the body weight. The therapeutic window for this drug is from 2 to 10 μ g/mL. Adverse toxicity is often observed at drug concentrations above 15 μ g/mL. The drug will be given by multiple IV bolus injections.
 - **a.** Calculate the dose for an adult male patient (68 years old, 82 kg) with normal renal function to be given every 8 hours.
 - **b.** Calculate the anticipated C_{\max}^{∞} and C_{\min}^{∞} values.
 - **c.** Calculate the C_{av}^{∞} value.
 - **d.** Comment on the adequacy of your dosage regimen.
- Tetracycline hydrochloride (Achromycin V, Lederle) is prescribed for a young adult male patient (28 years old, 78 kg) suffering from gonorrhea. According to the literature, tetracycline HCl is 77% orally absorbed, is 65% bound to plasma proteins, has an apparent volume of distribution of 0.5 L/kg, has an elimination half-life of 10.6 hours, and is 58% excreted unchanged in the urine. The minimum inhibitory drug concentration (MIC) for gonorrhea is 25–30 µg/mL.
 - **a.** Calculate an *exact* maintenance dose for this patient to be given every 6 hours around the clock.
 - **b.** Achromycin V is available in 250- and 500-mg capsules. How many capsules (state dose) should the patient take every 6 hours?
 - c. What loading dose using the above capsules would you recommend for this patient?

11. The body clearance of sumatriptan (Imitrex) is 250 mL/min. The drug is about 14% bioavailable. What would be the average plasma drug concentration after 5 doses of 100 mg PO every 8 hours in a patient? (Assume steady state was reached.)

ANSWERS

Frequently Asked Questions

Is the drug accumulation index (R) applicable to any drug given by multiple doses or only to drugs that are eliminated slowly from the body?

• Accumulation index, R, is a ratio that indicates steady-state drug concentration to the drug concentration after the first dose. The accumulation index does not measure the absolute size of overdosing; it measures the amount of drug cumulation that can occur due to frequent drug administration. Factors that affect *R* are the elimination rate constant, *k*, and the dosing interval, τ . If the first dose is not chosen appropriately, the steady-state level may still be incorrect. Therefore, the first dose and the dosing interval must be determined correctly to avoid any significant drug accumulation. The accumulation index is a good indication of accumulation due to frequent drug dosing, applicable to any drug, regardless of whether the drug is bound to tissues.

What are the advantages/disadvantages for giving a drug by constant IV infusion, intermittent IV infusion, or multiple IV bolus injections? What drugs would most likely be given by each route of administration? Why?

• Some of the advantages of administering a drug by constant IV infusion include the following: (1) A drug may be infused continuously for many hours without disturbing the patient. (2) Constant infusion provides a stable blood drug level for drugs that have a narrow therapeutic index. (3) Some drugs are better tolerated when infused slowly. (4) Some drugs may be infused simultaneously with electrolytes or other infusion media in an acute-care setting. Disadvantages of administering a drug by constant IV infusion include the following: (1) Some drugs

12. Cefotaxime has a volume of distribution of 0.17 L/kg and an elimination half-life of 1.5 hours. What is the peak plasma drug concentration in a patient weighing 75 kg after receiving 1 g IV of the drug 3 times daily for 3 days?

are more suitable to be administered as an IV bolus injection. For example, some reports show that an aminoglycoside given once daily resulted in fewer side effects compared with dividing the dose into two or three doses daily. Due to drug accumulation in the kidney and adverse toxicity, aminoglycosides are generally not given by prolonged IV infusions. In contrast, a prolonged period of low drug level for penicillins and tetracyclines may not be so efficacious and may result in a longer cure time for an infection. The pharmacodynamics of the individual drug must be studied to determine the best course of action. (2) Drugs such as nitroglycerin are less likely to produce tolerance when administered intermittently versus continuously.

Why is the steady-state peak plasma drug concentration often measured sometime after an IV dose is given in a clinical situation?

• After an IV bolus drug injection, the drug is well distributed within a few minutes. In practice, however, an IV bolus dose may be administered slowly over several minutes or the drug may have a slow distribution phase. Therefore, clinicians often prefer to take a blood sample 15 minutes or 30 minutes after IV bolus injection and refer to that drug concentration as the peak concentration. In some cases, a blood sample is taken an hour later to avoid the fluctuating concentration in the distributive phase. The error due to changing sampling time can be large for a drug with a short elimination half-life.

Is a loading dose always necessary when placing a patient on a multiple-dose regimen? What are the determining factors?

• A loading or priming dose is used to rapidly raise the plasma drug concentration to therapeutic drug levels to obtain a more rapid pharmacodynamic response. In addition, the loading dose along with the maintenance dose allows the drug to reach steady-state concentration quickly, particularly for drugs with long elimination half-lives.

An alternative way of explaining the loading dose is based on clearance. After multiple IV dosing, the maintenance dose required is based on Cl, C_{ss} , and τ .

$$C_{SS} = \frac{\text{Dose}}{\tau Cl}$$

Dose = $C_{SS} \tau Cl$

If C_{ss} and τ are fixed, a drug with a smaller clearance requires a smaller maintenance dose. In practice, the dosing interval is adjustable and may be longer for drugs with a small *Cl* if the drug does not need to be dosed frequently. The steady-state drug level is generally determined by the desired therapeutic drug.

Does a loading dose significantly affect the steadystate concentration of a drug given by a constant multiple-dose regimen?

• The loading dose will affect only the initial drug concentrations in the body. Steady-state drug levels are obtained after several elimination half-lives (eg, $4.32t_{1/2}$ for 95% steady-state level). Only 5% of the drug contributed by the loading dose will remain at 95% steady state. At 99% steady-state level, only 1% of the loading dose will remain.

Learning Questions

1. $V_{\rm D} = 0.20(50 \text{ kg}) = 10,000 \text{ mL}$

a.
$$D_{\text{max}} = \frac{D_0}{1 - f} = \frac{50 \text{ mg}}{1 - e^{-(0.693/2)(8)}} = 53.3 \text{ mg}$$

 $C_{\text{max}} = \frac{D_{\text{max}}}{V_{\text{D}}} = \frac{53.3 \text{ mg}}{10,000 \text{ mL}} = 5.33 \ \mu\text{g/mL}$
b. $D_{\text{min}} = 53.3 - 50 = 3.3 \text{ mg}$

$$C_{\min} = \frac{3.3 \text{ mg}}{10,000 \text{ mL}} = 0.33 \ \mu\text{g/mL}$$

c.
$$C_{av}^{\infty} = \frac{PD_0 1.44t_{1/2}}{V_D \tau}$$

 $= \frac{(50)(1.44)(2)}{(10,000)(8)} = 1.8 \ \mu g/mL$
2. a. $D_0 = \frac{C_{av}^{\infty}V_D \tau}{1.44t_{1/2}}$
 $= \frac{(10)(40,000)(6)}{(1.44)(5)}$
 $= 333 \ \text{mg every 6 h}$
b. $\tau = \frac{FD_0 1.44t_{1/2}}{V_D C_{av}^{\infty}}$
 $= \frac{(225,000)(1.44)(5)}{(40,000)(10)} = 4.05 \ \text{h}$

ED 1 11+

6. Dose the patient with 200 mg every 3 hours.

$$D_{\rm L} = \frac{D_0}{1 - e^{-k\tau}} = \frac{200}{1 - e^{-(0.23)(3)}} = 400 \text{ mg}$$

Notice that $D_{\rm L}$ is twice the maintenance dose, because the drug is given at a dosage interval equal approximately to the $t_{1/2}$ of 3 hours.

8. The plasma drug concentration, C_p , may be calculated at any time after *n* doses by Equation 9.21 and proper substitution.

$$C_{\rm p} = \frac{D_0}{V_{\rm D}} \left(\frac{1 - e^{-nk\tau}}{1 - e^{-k\tau}} \right) e^{-kt}$$
$$C_{\rm p} = \frac{200}{40} \left(\frac{1 - e^{-(3)(0.347)(4)}}{1 - e^{-(0.347)(4)}} \right) e^{-(0.347)(1)}$$
$$= 4.63 \text{ mg/L}$$

Alternatively, one may conclude that for a drug whose elimination $t_{1/2}$ is 2 hours, the predicted plasma drug concentration is approximately at steady state after 3 doses or 12 hours. Therefore, the above calculation may be simplified to the following:

$$C_{\rm p} = \frac{D_0}{V_{\rm D}} \left(\frac{1}{1 - e^{-k\tau}} \right) e^{-k\tau}$$
$$C_{\rm p} = \left(\frac{200}{40} \right) \left(\frac{1}{1 - e^{-(0.347)(4)}} \right) e^{-(0.347)(1)}$$
$$= 4.71 \text{ mg/L}$$

228 Chapter 9

9.
$$C_{\max}^{\infty} = \frac{D_0 / V_D}{1 - e^{-k\tau}}$$

where

$$V_{\rm D} = 20\% \text{ of } 82 \text{ kg} = (0.2)(82) = 16.4 \text{ L}$$

$$k = (0.693/3) = 0.231 \text{ h}^{-1}$$

$$D_0 = V_{\rm D} C_{\rm max}^{\infty} (1 - e^{-k\tau}) = (16.4)(10)(1 - e^{-(0.231)(8)})$$
a. $D_0 = 138.16 \text{ mg}$ to be given every 8 hours
b. $C_{\rm min}^{\infty} = C_{\rm max}^{\infty} (e^{-k\tau}) = (10)(e^{-(0.231)(8)})$

$$= 1.58 \text{ mg/L}$$
c. $C_{\rm av}^{\infty} = \frac{D_0}{kV_{\rm D}\tau} = \frac{138.16}{(0.231)(16.4)(8)}$

=4.56 mg/L

d. In the above dosage regimen, the C_{\min}^{∞} of 1.59 mg/L is below the desired C_{\min}^{∞} of 2 mg/L. Alternatively, the dosage interval, τ , could be changed to 6 hours.

$$D_0 = V_D C_{max}^{\infty} (1 - e^{-k\tau}) = (16.4)(10)(1 - e^{-(0.231)(6)})$$

 $D_0 = 123$ mg to be given every 6 h

$$C_{\min}^{\infty} = C_{\max}^{\infty}(e^{-k\tau}) = (10)(e^{-(0.231)(6)}) = 2.5 \text{ mg/L}$$

$$C_{\rm av}^{\infty} = \frac{D_0}{kV_{\rm D}\tau} = \frac{123}{(0.231)(16.4)(6)} = 5.41 \text{ mg/L}$$

REFERENCES

- Jefferson JW, Pradko JF, Muir KT: Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. *Clin Ther* 27(11):1685–1695, 2005.
- Kruger-Thiemer E: Pharmacokinetics and dose-concentration relationships. In Ariens EJ (ed.), *Physico-Chemical Aspects of Drug Action.* New York, Pergamon, 1968, p 97.
- Niebergall PJ, Sugita ET, Schnaare RC: Potential dangers of common drug dosing regimens. Am J Hosp Pharm 31:53–59, 1974.
- Primmett D, Levine M, Kovarik, J, Mueller E, Keown, P: Cyclosporine monitoring in patients with renal transplants: Two- or

10. a. $C_{av}^{\infty} = \frac{FD_0}{kV_D\tau}$ Let $C_{av}^{\infty} = 27.5 \text{ mg/L}$

$$D_0 = \frac{C_{av} k V_D \tau}{F} = \frac{(27.5)(0.693710.6)(0.5)(78)(6)}{0.77}$$

= 546.3 mg

 $D_0 = 546.3 \text{ mg every } 6 \text{ h}$

b. If a 500-mg capsule is given every 6 hours,

$$C_{\rm av}^{\infty} = \frac{FD_0}{kV_{\rm D}\tau} = \frac{(0.77)(500)}{(0.693/10.6)(0.5)(78)(6)}$$
$$= 25.2 \text{ mg/L}$$

C.
$$D_{\rm L} = \frac{D_{\rm M}}{1 - e^{-k\tau}} = \frac{500}{1 - e^{(0.654)(6)}} = 1543 \text{ mg}$$

 $D_{\rm L} = 3 \times 500 \text{ mg capsules} = 1500 \text{ mg}$

- three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure, therapeutic drug monitoring **20**(3):276–283, June 1998.
- Sawchuk RJ, Zaske DE: Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamycin in burn patients. J Pharmacokin Biopharm 4(2):183–195, 1976.
- van Rossum JM, Tomey AHM: Rate of accumulation and plateau concentration of drugs after chronic medication. J Pharm Pharmacol 30:390–392, 1968.

BIBLIOGRAPHY

- Gibaldi M, Perrier D: *Pharmacokinetics*, 2nd ed. New York, Marcel Dekker, 1962, pp 451–457.
- Levy G: Kinetics of pharmacologic effect. *Clin Pharmacol Ther* **7:**362, 1966.
- van Rossum JM: Pharmacokinetics of accumulation. *J Pharm Sci* **75:**2162–2164, 1968.
- Wagner JG: Kinetics of pharmacological response, I: Proposed relationship between response and drug concentration in the intact animal and man. *J Theor Biol* **20**:173, 1968.
- Wagner JG: Relations between drug concentrations and response. *J Mond Pharm* **14:**279–310, 1971.